Advertisement

Ads Placeholder
Loading...

Biogen Inc.

BIIB•NASDAQ
Healthcare
Drug Manufacturers - General
$177.34
$-6.44(-3.50%)
U.S. Market opens in 3h 59m

Biogen Inc. (BIIB) Stock Overview

Explore Biogen Inc.’s financial performance, market position, analyst ratings, and future outlook.

Meyka AI Score

Z

Key Financials

Market Cap26B
P/E Ratio20.11
EPS (TTM)$8.80
ROE0.07%
Fundamental Analysis

AI Price Forecasts

1 Month$165.81
3 Months$241.82
1 Year Target$115.21

BIIB Stock Analysis & Investment Overview

Our comprehensive AI-powered analysis of Biogen Inc. (BIIB) provides investors with deep insights into the stock's performance, growth potential, and market positioning. With a Meyka AI Score of B+, this stock demonstrates moderate investment characteristics based on our advanced machine learning models.

The current technical analysis reveals key indicators including an RSI of 40.54, suggesting the stock is in a neutral condition. Our forecasting models predict significant price movements, with a 12-month target of $115.21.

Key financial metrics showcase the company's fundamental strength, including a P/E ratio of 20.11 and a market capitalization of 26B. These metrics, combined with our AI analysis, provide a comprehensive view for both institutional and retail investors.

1-Day Change
-3.50%
5-Day Change
-7.18%
1-Month Change
-3.63%
3-Month Change
-0.27%
6-Month Change
10.92%
Year-to-Date (YTD) Change
-0.27%
1-Year Change
35.67%
3-Year Change
-36.06%
5-Year Change
-36.18%
All-Time (Max) Change
5574.88%

Contact Information

https://www.biogen.com
617 679 2000
225 Binney Street, Cambridge, MA, 02142

Company Facts

76,050 Employees
IPO DateSep 17, 1991
CountryUS
Actively Trading

Frequently Asked Questions